-
- Positions
- PROFESSOR | Psychiatry
- PROFESSOR | Pediatrics
-
- Specialty
- Child and Adolescent Psychiatry
-
- Language
- English
-
- Hospital Affiliation
- The Mount Sinai Hospital
-
- Phone
- 212-659-8705212-659-8705
Dr. Newcorn is a highly-regarded researcher in the areas of Attention-Deficit/Hyperactivity Disorder (ADHD), aggression, descriptive psychopathology of child and adolescent disorders, and child and adolescent psychopharmacology. His work spans both clinical and translational topics. He is a member of the steering committee of the NIMH-funded multicenter study “Multimodal Treatment of Children with ADHD (MTA).” He was a member of the DSM-IV advisory committees on child and adolescent disorders and disruptive behavior disorders. He is the primary investigator on a NIMH-funded ADHD Research Infrastructure Network devoted to understanding the neurobiology of ADHD, and is the principle investigator or co-investigator on several NIMH-funded grants that examine the clinical, genetic, neuroanatomic and neurophysiologic basis of ADHD its treatment. He is a nationally recognized educator and mentor, and is the primary or secondary mentor on five NIMH training grants. He is an editorial board member of several leading child psychiatry and psychology journals, and conducts ad hoc reviews for many other leading psychiatry journals, and NIMH. Dr. Newcorn directs an active clinical trials program, and has studied many of the newer medication treatments for ADHD. He has published over 150 peer-reviewed articles and book chapters on these and related subjects.
Certifications
Am Board of Psychiatry & Neurology (Sub: Child)
Psychiatry, American Board of Psychiatry and Neurology
Clinical Focus
- Attention Deficit Hyperactivity Disorder And Attention Deficit Disorder
Education
MD, University of Rochester School of Medicine & Dentistry
Residency, Psychiatry
New England Medical Center
Residency, Psychiatry
New England Medical Center
Fellowship, Child and Adolescent Psychiatry
New England Medical Center
Language
English
Clinical Trials
Efficacy of Lisdexamfetamine in Adults with ADHD and Sluggish Cognitive Tempo (SCT)
Although Sluggish Cognitive Tempo (SCT) may represent a clinically meaningful condition with distinct underlying pathophysiology that differs from ADHD, research indicates that SCT is common among adults with ADHD. We will investigate treatment response of adults with ADHD and SC...
A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared with OROS-MPH (CONCERTA®) with a Placebo Reference Arm, in Adolescents Aged 13-17 Years with Attention-deficit/Hyperactivity Disorder (ADHD)
This trial is examining the use of Concerta or Vyvanse in adolescents ages 13-17 who have ADHD. The purpose of this study is to examine the response to two commonly prescribed stimulant medications that are FDA approved for treatment of ADHD in children and adolescents. The...
Attention Deficit Hyperactivity Disorder Study
The purpose of this study is to examine the response to a commonly prescribed medication that is FDA approved for treatment of ADHD in children and adolescents. The study will include weekly visits with study physicians, evaluations for ADHD and other disorders, and medication fo...
Imaging Stimulant and Non-Stimulant Treatments for ADHD: A Network Based Approach
This study represents an important first step in developing an individualized approach to treatment selection in youth with ADHD, in keeping with our agenda highlighting personalized approaches to clinical care. We are recruiting 80 youth with ADHD and 40 healthy children without...
Neurobiological Basis of Response to Vyvanse in Adults with ADHD: An fMRI Study of Brain Activation
The purpose of this study is to examine response to a commonly prescribed medication that is FDA approved for treatment of ADHD in adults. The study will include weekly visits with study physicians, evaluations for ADHD and other disorders, and medication for the treatment of ADH...
Predicting Response to Atomoxetine and Methylphenidate
The purpose of this study is three-fold. First, to compare the efficacy of four to five weeks of treatment with methylphenidate (Concerta™) and atomoxetine (Strattera™) on ADHD symptoms and associated functional impairment. Second, to evaluate differences in adverse effects and p...
Attention Deficit Hyperactivity Disorder Study: Methylphenidate v. Atomoxetine
The purpose of this federally-funded research study is to examine and compare mechanisms of action of two FDA approved medications for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). If volunteers are participating in the medication treatment study that examines...
Neurobiological Basis of Response to Vayarin® in Adults with ADHD: an fMRI Study of Brain Activation Pre and Post Treatment
Our prior research suggests that effective non-stimulant treatments for ADHD act through key prefrontal regions that subserve inhibitory and executive functions, although different medications may achieve these effects via distinct mechanisms. The objective of this research is to...
Volkow ND, Wang GJ, Newcorn J, Telang F, Solanto MV, Fowler JS, Logan J, Ma Y, Schulz K, Pradhan K, Wong C, Swanson JM. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. Archives of general psychiatry 2007 Aug; 64(8).
Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, Michelson D. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. The American journal of psychiatry 2008 Jun; 165(6).
Schulz KP, Clerkin SM, Halperin JM, Newcorn JH, Tang CY, Fan J. Dissociable neural effects of stimulus valence and preceding context during the inhibition of responses to emotional faces. Human brain mapping 2009 Sep; 30(9).
Volkow ND, Wang GJ, Kollins SH, Wigal TL, Newcorn JH, Telang F, Fowler JS, Zhu W, Logan J, Ma Y, Pradhan K, Wong C, Swanson JM. Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA : the journal of the American Medical Association 2009 Sep; 302(10).
Clerkin SM, Schulz KP, Halperin JM, Newcorn JH, Ivanov I, Tang CY, Fan J. Guanfacine potentiates the activation of prefrontal cortex evoked by warning signals. Biological psychiatry 2009 Aug; 66(4).
Newcorn JH, Sutton VK, Zhang S, Wilens T, Kratochvil C, Emslie GJ, D'souza DN, Schuh LM, Allen AJ. Characteristics of placebo responders in pediatric clinical trials of attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry 2009 Dec; 48(12).
Newcorn JH, Sutton VK, Weiss MD, Sumner CR. Clinical responses to atomoxetine in attention-deficit/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study. Journal of the American Academy of Child and Adolescent Psychiatry 2009 May; 48(5).
Solanto MV, Schulz KP, Fan J, Tang CY, Newcorn JH. Event-related FMRI of inhibitory control in the predominantly inattentive and combined subtypes of ADHD. Journal of neuroimaging : official journal of the American Society of Neuroimaging 2009 Jul; 19(3).
Bédard AC, Schulz KP, Cook EH, Fan J, Clerkin SM, Ivanov I, Halperin JM, Newcorn JH. Dopamine transporter gene variation modulates activation of striatum in youth with ADHD. NeuroImage 2010 Nov; 53(3).
Volkow ND, Wang GJ, Newcorn JH, Kollins SH, Wigal TL, Telang F, Fowler JS, Goldstein RZ, Klein N, Logan J, Wong C, Swanson JM. Motivation deficit in ADHD is associated with dysfunction of the dopamine reward pathway. Molecular psychiatry 2010 Sep;.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Newcorn during 2016 and/or 2017. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- Alcobra Ltd., ILSI
- Enzymotec, Ltd.
- GencoSciences LLC
- Shire
- Sunovion Pharmaceuticals Inc.
Other activities: Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
- Alcobra Ltd., ILSI
- GencoSciences LLC
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
Scientific Advisory Board:
- BioBehavioral Diagnostics Company
- Enzymotec, Ltd.
- Lupin Pharmaceuticals, Inc.
- Neurovance
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.